跳至主要内容
临床试验/NCT00075842
NCT00075842已完成3 期

The Use Of Valeriana Officinalis (Valerian) In Improving Sleep In Patients Who Are Undergoing Adjuvant Treatment For Cancer" A Phase III Randomized, Placebo-Controlled, Double-Blind Study

Alliance for Clinical Trials in Oncology33 个研究点 分布在 1 个国家目标入组 227 人开始时间: 2003年8月1日最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
入组人数
227
试验地点
33
主要终点
Insomnia occurrence by Pittsburg Sleep Inventory at 6 weeks

研究概览

简要总结

RATIONALE: The herb Valeriana officinalis (valerian) may promote sleep. It is not yet known whether valerian is effective in improving sleep in patients who are receiving adjuvant therapy for cancer.

PURPOSE: This randomized phase III trial is studying how well valerian improves the quality of sleep in patients who are receiving adjuvant therapy (radiation therapy, chemotherapy, or hormone therapy) for cancer.

详细描述

OBJECTIVES:

Primary

  • Determine the effect of Valeriana officinalis (Valerian) for improving the quality of sleep in patients with cancer receiving adjuvant therapy.

Secondary

  • Determine the safety of this therapy, in terms of frequency and severity of adverse events, in these patients.
  • Determine the effect of this therapy on the degree of anxiety, fatigue, and activities of daily living in these patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •DISEASE CHARACTERISTICS:
  • •Diagnosis of cancer
  • •Receiving adjuvant therapy, including any of the following:
  • •Radiotherapy
  • •Parenteral chemotherapy
  • •Oral drugs
  • •Hormonal therapy
  • •Previously resected tumor, microscopic disease, or nodal or margin involvement allowed
  • •Patients receiving intended curative treatment without future planned surgery (i.e., prostate cancer patients receiving radiotherapy followed by hormonal therapy) are eligible
  • •Reports difficulty sleeping and seeking therapeutic intervention
  • •Defined as a score over 3 on the numerical analogue scale
  • •No obstructive sleep apnea
  • •No prior diagnosis of primary insomnia per DSM IV criteria
  • •PATIENT CHARACTERISTICS:
  • •18 and over
  • •Performance status
  • •Life expectancy
  • •At least 6 months
  • •SGOT ≤ 1.5 times upper limit of normal (ULN)
  • •Alkaline phosphatase ≤ 1.5 times ULN
  • •Not pregnant or nursing
  • •Negative pregnancy test
  • •Fertile patients must use effective contraception
  • •No chronic symptom that consistently interrupts sleep (e.g., hot flashes, unmanaged pain, or diarrhea)
  • •PRIOR CONCURRENT THERAPY:
  • •No prior Valeriana officinalis (Valerian) for sleep
  • •More than 1 month since other prior prescription sleeping-aid medication
  • •No concurrent benzodiazepines except as short-term treatment for nausea

排除标准

  • 未提供

研究组 & 干预措施

Arm I

Experimental

Patients receive oral Valeriana officinalis (Valerian) once daily for 8 weeks.

干预措施: Valeriana officinalis extract (Dietary Supplement)

Arm II

Placebo Comparator

Patients receive an oral placebo once daily for 8 weeks.

干预措施: placebo (Other)

结局指标

主要结局

Insomnia occurrence by Pittsburg Sleep Inventory at 6 weeks

时间窗: at 6 weeks

次要结局

  • Toxicity by questionnaires weekly and CTC grading every 2 weeks(Up to 2 weeks post-treatment)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (33)

Loading locations...

相似试验